Evolution of the Average Target: AbbVie Inc.

Evolution of the Target Price: AbbVie Inc.

Changes in Analyst Recommendations: AbbVie Inc.

ad1dc4b594a77b833e8d8b70cd8e80.XRUa0ED0nvJEuqy-AijViw2DS9KZPgt67geRxw4lafs.BXRNlAyC84cAwOPURn6NzXqufaesX2AvtEHQvUlxPagrcFi6Ob_MlzGOmA~68b615f978b163d25178051632649b66
May. 14 Piper Sandler Adjusts Price Target on AbbVie to $298 From $294, Maintains Overweight Rating MT
May. 05 Daiwa Securities Adjusts AbbVie Price Target to $237 From $244, Maintains Outperform Rating MT
Apr. 30 Morgan Stanley Adjusts Price Target on AbbVie to $278 From $270 MT
Apr. 30 Goldman Sachs Adjusts AbbVie Price Target to $244 From $240 MT
Apr. 30 AbbVie Expected to Post Durable Growth Into Mid-2030s, BofA Securities Says MT
Apr. 30 BofA Securities Upgrades AbbVie to Buy From Neutral MT
Apr. 23 Piper Sandler Adjusts Price Target on AbbVie to $294 From $299, Maintains Overweight Rating MT
Apr. 21 Canaccord Genuity Initiates AbbVie at Buy With $262 Price Target MT
Apr. 15 Johnson & Johnson Reported Above-Peer Topline Growth in Q1, BofA Says MT
Apr. 13 Evercore ISI Adjusts AbbVie Price Target to $232 From $233, Maintains Outperform Rating MT
Apr. 10 AbbVie First-Quarter Earnings Unlikely to Lift Sentiment, RBC Says MT
Apr. 10 Guggenheim Adjusts Price Target on AbbVie to $249 From $242, Maintains Buy Rating MT
Apr. 09 Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says MT
Apr. 08 Cantor Fitzgerald Adjusts Price Target on AbbVie to $240 From $250, Maintains Overweight Rating MT
Mar. 09 Global markets live: Live Nation, Eli Lilly, Amazon, Microsoft, ABB… Zonebourse
Mar. 05 Evercore ISI Adjusts AbbVie Price Target to $233 From $228, Maintains Outperform Rating MT
Feb. 25 AbbVie Could See Continued Outperformance Despite Market Concerns, RBC Capital Markets Says MT
Feb. 19 Daiwa Securities Raises AbbVie Price Target to $244 From $226, Maintains Outperform Rating MT
Feb. 18 Piper Sandler Adjusts Price Target on AbbVie to $299 From $289, Maintains Overweight Rating MT
Feb. 17 HSBC Adjusts Price Target on AbbVie to $275 From $265, Maintains Buy Rating MT
Feb. 09 BNP Paribas Exane Adjusts Price Target on AbbVie to $213 From $203, Maintains Neutral Rating MT
Feb. 05 Evercore ISI Adjusts Price Target on AbbVie to $228 From $232, Maintains Outperform Rating MT
Feb. 05 Goldman Sachs Adjusts Price Target on AbbVie to $240 From $223, Maintains Neutral Rating MT
Feb. 05 UBS Adjusts AbbVie Price Target to $230 From $240, Maintains Neutral Rating MT
Feb. 05 Morgan Stanley Lifts Price Target on AbbVie to $270 From $269, Keeps Overweight Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+21.31%
+19.12%
+9.78%
+12.74%
+19.29%
+4.09%
+14.36%
+2.94%
+4.69%
+18.73%
Average +12.71%
Weighted average by Cap. +14.05%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
210.77USD
Average target price
252.93USD
Spread / Average Target
+20.00%
High Price Target
328.00USD
Spread / Highest target
+55.62%
Low Price Target
184.00USD
Spread / Lowest Target
-12.70%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Piper Sandler
Daiwa Securities
Morgan Stanley
Goldman Sachs
BofA Securities
Canaccord Genuity
Evercore ISI
Guggenheim
Cantor Fitzgerald
HSBC
BNP Paribas
UBS
Citigroup
Berenberg Bank
Leerink Partners
Rothschild & Co Redburn
Wolfe Research
Argus
Scotiabank
Bernstein
JPMorgan Chase
Raymond James
BNP Paribas Exane
BMO Capital
TD Cowen
Deutsche Bank Securities
Wells Fargo Securities
DBS Bank
Ameriprise Financial
Redburn Atlantic
Truist Securities
Barclays
Mizuho Securities
Morningstar
William Blair & Co.
Atlantic Equities
SVB Securities LLC
Credit Suisse
Societe Generale
Cowen
Redburn
SVB Leerink
RBC Capital Markets
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
210.77USD
Average target price
252.93USD
Spread / Average Target
+20.00%

Quarterly revenue - Rate of surprise